1. Home
  2. PHAR vs IVA Comparison

PHAR vs IVA Comparison

Compare PHAR & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

N/A

Current Price

$11.57

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

N/A

Current Price

$4.63

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PHAR
IVA
Founded
1988
2011
Country
Netherlands
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
PHAR
IVA
Price
$11.57
$4.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
10
Target Price
$38.33
$16.20
AVG Volume (30 Days)
18.0K
691.2K
Earning Date
05-07-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$10.04
N/A
Revenue Next Year
$2.51
$751.20
P/E Ratio
$3,041.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.62
$3.35
52 Week High
$21.34
$7.98

Technical Indicators

Market Signals
Indicator
PHAR
IVA
Relative Strength Index (RSI) 47.53 53.04
Support Level $9.62 $4.48
Resistance Level $17.89 $4.70
Average True Range (ATR) 0.67 0.19
MACD 0.15 -0.01
Stochastic Oscillator 58.51 54.86

Price Performance

Historical Comparison
PHAR
IVA

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.

Share on Social Networks: